First Phase III results for perampanel in epilepsy look positive
This article was originally published in Scrip
Executive Summary
Eisai has reported positive results from the first Phase III clinical study with its non-competitive AMPA glutamate antagonist perampanel (E2007) as an adjunctive therapy in epilepsy patients with refractory partial seizures.